US Patent 10,786,500 Landscape and Claim Scope for Crystalline Hemifumarate Oral Compositions
Executive summary. US Patent 10,786,500 covers an oral pharmaceutical composition and tablets containing 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide hemifumarate in a high-crystallinity form (crystals are ≥62% by amount) combined with specific excipients (lactose, D-mannitol, anhydrous dibasic calcium phosphate, calcium stearate, talc). Dependent claims narrow to additive weight fractions (50–90% w/w), preferred excipient selections (notably D-mannitol and/or lactose), and tablet dosage form. From a freedom-to-operate (FTO) and Paragraph IV/biosimilar-style risk lens, the core infringement hook is whether a generic or follow-on product uses the same hemifumarate drug substance and meets the claimed crystalline proportion plus excipient selections and weight ranges, not the synthesis route of the API.
What claims does US Patent 10,786,500 have for crystalline hemifumarate tablets?
Claim 1 is the independent claim: composition with crystallinity + specific additives
Claim 1 defines infringement on four pillars:
-
Drug substance identity (exact API form name).
The API is precisely: 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide hemifumarate.
-
Crystalline proportion threshold (≥62% of crystals by amount).
The claim requires that the proportion of crystals of the hemifumarate is 62% or more relative to the total amount of the same hemifumarate in the composition.
-
At least one enumerated additive (excipient selection).
The composition includes at least one pharmaceutical additive from:
- lactose
- D-mannitol
- anhydrous dibasic calcium phosphate
- calcium stearate
- talc
-
Oral administration format (composition level).
The composition is for oral administration, but Claim 1 is not limited to tablet only; that is covered by Claim 8/9.
Practical scope meaning. A product can infringe Claim 1 even if it uses only one of the listed excipients, as long as it hits the API form and crystallinity threshold.
Dependent claims 2–7 narrow excipient loading and excipient choice
- Claim 2: total pharmaceutical additive content is 50% to 90% by weight of the total composition.
- Claim 3: additive is D-mannitol.
- Claim 4: additive is lactose and/or D-mannitol.
- Claim 5: additive is D-mannitol (dependent from Claim 2/4 path).
- Claim 6: total lactose and/or D-mannitol is 50% to 70% by weight.
- Claim 7: total D-mannitol is 50% to 70% by weight.
Practical scope meaning. Claim 1 can be met with minimal additive use (since it only says “at least one”). Claim 2 makes a higher-level “formulation ratio” requirement for infringement of the dependent claim sets. Claims 3/4/6/7 create specific excipient-heavy formulation versions that are easier to target in practice if a product uses mannitol and/or lactose in bulk.
Claim 8 and Claim 9 lock in tablet dosage form and combined limitations
- Claim 8: composition is a tablet (dependent on Claim 1 and certain dependency paths).
- Claim 9: tablet comprising the API hemifumarate with:
- additive selection from: lactose, D-mannitol, anhydrous dibasic calcium phosphate, calcium stearate, talc (note: your text shows “an talc,” which is clearly talc)
- total pharmaceutical additive content 50–90% w/w
- crystal proportion ≥62%
Practical scope meaning. Claim 9 is the strongest “product-shape” claim. A tablet manufacturer that uses (i) the same hemifumarate API form, (ii) a crystalline content at/above 62%, and (iii) the enumerated excipients at the required overall loading is in the core claim zone.
Claims 10 and 11 narrow tablet excipient identity
- Claim 10: lactose and/or D-mannitol.
- Claim 11: D-mannitol.
How is “crystals ≥62%” likely to be litigated under US claim construction?
The technical hinge: measured crystallinity of hemifumarate
The claim is a process-independent formulation property: crystallinity is a state of the solid API in the final dosage form (or at least the API as present in the composition). In infringement disputes, the focus typically becomes:
- what method is used to quantify crystal proportion (not specified in your excerpt),
- whether the API batch as blended into tablets meets the numerical threshold,
- sampling and measurement variability,
- whether “crystals” includes polymorphs, hydrates/solvates, or amorphous content, and how “hemifumarate” is confirmed.
Claim coverage is not just “hemifumarate” but “hemifumarate with sufficient crystalline content”
Because the threshold is specific, a design-around strategy that replaces part of the API with non-crystalline/less-crystalline material could, in theory, avoid the ≥62% requirement. But the claim is tied to “a proportion of crystals… is 62% or more,” so any formulation that ends up with ≥62% remains within scope regardless of how it was manufactured.
Why crystallinity threshold drives FTO and generic risk
For generics, the usual route is to meet quality standards, replicate the API form, and blend excipients to a target dissolution profile. This patent forces an additional target: the crystalline content must exceed a numeric threshold. That creates potential testing and proof burdens in litigation.
What patent estate issues does US 10,786,500 raise if your product uses the same hemifumarate API?
This patent is an oral formulation patent, not a method-of-treatment claim
From the claim language, the estate is oriented to:
- solid-state formulation design (crystallinity proportion),
- excipient selection and ratio,
- tablet dosage form.
That matters because a generic can sometimes avoid formulation patents by changing dosage form or avoiding claimed excipient sets and ratios, but only if doing so does not collide with other patents in the broader API solid-state or formulation families.
Likely claim clusters in the same family (based on typical drafting patterns)
Even without the full specification, the independent claim structure suggests a family that may include:
- additional claims around tablet formulations,
- claims around other excipient combinations,
- claims around other crystallinity ranges or measurement definitions,
- claims on solid-state forms of the hemifumarate (polymorph/crystal form designations) that could sit upstream.
Your excerpt shows formulation-level claims; it does not show a polymorph designation beyond the hemifumarate itself plus a crystallinity percentage.
Which product design choices would most directly avoid or trigger infringement under these claims?
High-infringement configurations
A tablet is most exposed if it does all of the following:
- Uses the specific hemifumarate API identity.
- Has crystalline proportion ≥62% in the blended tablet composition.
- Contains at least one of the listed excipients, especially:
- D-mannitol,
- lactose,
- calcium stearate,
- talc,
- anhydrous dibasic calcium phosphate.
- Uses total additive loading 50–90% w/w, if targeting dependent claim territory (Claim 2/6/7/9).
Potential design-around levers (claim-language level)
- Crystallinity shift below 62%: If a formulation uses the same hemifumarate but results in <62% crystals (as measured per the relevant testing/definition), it may avoid the numerical requirement of Claim 1/9.
- Excipient substitution: If the tablet avoids all enumerated additives (lactose, D-mannitol, anhydrous dibasic calcium phosphate, calcium stearate, talc), Claim 1’s “at least one additive from the group” fails. This is a hard lever because many tablets use lactose or mannitol.
- Tablet dosage form avoidance: Claim 9 is tablet-specific; Claim 1 is not. A non-tablet oral dosage form could avoid Claim 9 but still fall under Claim 1 if it is an “oral pharmaceutical composition” and meets the crystallinity + excipient selection constraints.
How many claims in US 10,786,500 are tied to excipient selection and loading?
Count by limitation type from your excerpt:
- Additive group selection (lactose/D-mannitol/dibasic calcium phosphate/calcium stearate/talc): appears in Claim 1 and Claim 9.
- Total additive loading 50–90% w/w: Claim 2 and Claim 9.
- Preferred excipient identity:
- D-mannitol only: Claim 3, Claim 5, Claim 7, Claim 11
- lactose and/or D-mannitol: Claim 4, Claim 6, Claim 10
- Tablet limitation: Claim 8 and Claim 9.
Net effect: The patent is “formulation-heavy.” Most meaningful claim protection is directed at how the solid API is formulated into oral tablets with common excipients.
What generic entry risks exist if a challenger files an ANDA using a different solid-state approach?
Risk factor 1: matching the API hemifumarate identity
If the generic uses a different salt or base form, the claims likely do not read on it due to the extremely specific API identity text in Claim 1/9.
Risk factor 2: meeting the ≥62% crystal proportion
If the generic uses the hemifumarate but produces a lower-crystallinity form, it may avoid Claim 1/9. If it ends up with equal-or-higher crystalline content, it is exposed.
Risk factor 3: excipients
Most ANDA tablet formulations use lactose and/or mannitol. That directly places them in the Claim 1/9 excipient set unless they substitute alternative excipients not listed.
Litigation posture implication
Because the claims hinge on measured properties (crystalline proportion) and formulation composition, infringement proof will likely focus on:
- analytical characterization of the API solid-state in finished product,
- excipient identification and quantification,
- batch-level crystallinity variability across multiple test lots.
What is the commercial coverage implied by the claim scope?
Target dosage form: tablets with common excipient-heavy formulations
The claim allows:
- high excipient loading (50–90% w/w),
- lactose and/or D-mannitol formulations,
- mannitol-dominant formulations (50–70% w/w for D-mannitol alone),
- mixed lactose/mannitol at 50–70% w/w combined.
That maps to a wide range of practical tablet compositions. The economic implication is that the patent likely blocks many generic formulation designs that rely on lactose/mannitol and typical filler levels.
Key Takeaways
- US 10,786,500 is a formulation patent focused on an oral tablet composition using a specific hemifumarate API in a high-crystallinity state (≥62% crystals).
- Core infringement requirements are conjunctive: correct API identity + crystallinity threshold + excipient group selection; dependent claims add excipient loading ranges and tablet format.
- Closest generic risk zone is a tablet that uses the same hemifumarate and conventional lactose/mannitol excipient systems with crystallinity at or above the threshold.
- Most direct design-arounds based on the claim text are to reduce crystallinity below 62% (as measured for infringement), use no listed excipients, or avoid tablet-only embodiments while still managing Claim 1 exposure for oral compositions.
FAQs
1) Does US 10,786,500 require the tablet to contain all excipients in the list?
No. Claim 1 requires at least one additive from the enumerated group.
2) Can a product infringe Claim 9 even if it uses fewer than 50% excipients?
No. Claim 9 requires total pharmaceutical additive content of 50–90% by weight.
3) If a generic uses the same hemifumarate API but produces crystals at 61%, is it within scope?
Claim 1/9 require ≥62% crystals, so a product at 61% would not meet the stated threshold.
4) Is the patent limited to tablets only?
Claim 9 is limited to tablets; Claim 1 covers oral pharmaceutical compositions generally, not only tablets.
5) Are lactose and D-mannitol mandatory?
No. Lactose and/or D-mannitol are mandatory only for certain dependent claims; Claim 1 needs only one additive from the specified list.
References
- United States Patent 10,786,500. (Patent claims excerpted from provided text).
